{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-039225","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.050368+00:00","generated_at":"2026-05-31T06:27:18.023876+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Absci completes first milestone in AstraZeneca oncology collaboration; AI-designed antibodies delivered","bullets":["Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.","AstraZeneca elected to advance sequences into AI-lead optimization phase.","Collaboration combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.","Goal: accelerate discovery of a potential new cancer treatment candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-039225","json":"https://secwatch.observer/filing/0001628280-24-039225.json","markdown":"https://secwatch.observer/filing/0001628280-24-039225.md","text":"https://secwatch.observer/filing/0001628280-24-039225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024039225/0001628280-24-039225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024039225/absc-20240904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:27:18.023876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}